HLS Therapeutics Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, HLS Therapeutics stock has a consensus rating of "Buy" and an average price target of $7.22. The average 1-year stock price forecast is 65.98% higher than the current stock price, while the lowest is $4.55 (+4.60%) and the highest is $12.16 (+179.54%).

Price Target: $7.22 (+65.98%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$4.55	$7.22	$6.07	$12.16
Change	+4.60%	+65.98%	+39.54%	+179.54%

Analyst Ratings

The average analyst rating for HLS Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Sep '25	Nov '25	Dec '25	Feb '26	Mar '26	May '26
Strong Buy	2	1	1	1	1	1
Buy	1	1	1	1	1	1
Hold	1	2	1	1	1	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	3	3	3	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Tania Armstrong-Whitworth Canaccord Genuity	Canaccord Genuity	Hold Initiates $5.00	Hold	Initiates	$5.00	+14.94%	May 19, 2026
David Martin PhD Bloom Burton	Bloom Burton	Buy Maintains $12.00	Buy	Maintains	$12.00	+175.86%	May 19, 2026
Justin Keywood Stifel Nicolaus	Stifel Nicolaus	Hold Maintains $4.75 → $4.45	Hold	Maintains	$4.75 → $4.45	+2.30%	Mar 12, 2026

Financial Forecast

Revenue This Year

58.03M

from 55.50M

4.56%

from 55.50M

Revenue Next Year

64.31M

from 58.03M

10.83%

from 58.03M

EPS This Year

-0.20

from -0.39

EPS Next Year

-0.03

from -0.20

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	60.01M	61.47M	63.07M	56.62M	55.50M	58.03M
Revenue Growth	6.95%	2.43%	2.61%	-10.23%	-1.98%	4.56%
Gross Profit	50.36M	50.76M	49.88M	41.96M	39.71M	46.95M
Gross Margin	83.92%	82.58%	79.08%	74.11%	71.55%	80.90%
Operating Income	-6.28M	-13.50M	-10.35M	-7.69M	-4.11M	-4.20M
Net Income	-13.12M	-23.60M	-27.53M	-19.66M	-12.43M	-6.26M
EPS	-	-	-	-	-0.39	-0.20
Free Cash Flow	12.13M	15.63M	24.71M	26.39M	19.64M	10.50M
No. Analysts	-	-	-	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	58.7M
Avg	58.0M
Low	57.5M

Revenue Growth

Revenue Growth	2026	2027	2028
High	5.8%
Avg	4.6%
Low	3.6%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.20
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-